A differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1/2 versus ATM mutations has been observed, in which patients with BRCA1/2 mutations respond to olaparib treatment but not those with ATM mutations [26]. This evidence concerns the gene BRCA1 and Familial prostate cancer.